Low Incidence of Rejection and De Novo Donor‐Specific Antibody Formation Following COVID ‐19 Vaccination or Infection Among Pediatric Kidney Transplant Recipients
- 29 April 2025
- journal article
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (4) , e70084
Abstract
Background: Studies in adults have demonstrated a risk for allograft rejection or development of donor‐specific antibodies (DSA) following SARS‐CoV‐2 vaccination. We examined the incidence of acute rejection and de novo DSA following COVID‐19 vaccination or infection among pediatric kidney transplant patients. Method: Retrospective analysis of 23 pediatric kidney transplant recipients without prior history of rejection, DSA, or COVID‐19 infection who received the SARS‐CoV‐2 mRNA vaccine. Risk for rejection was evaluated via monitoring of serum creatinine, DSA, and donor‐derived cell‐free DNA per center protocol. Results concerning for rejection prompted allograft biopsy, graded by the Banff classification system. Results: Eight of 23 (34.8%) received two doses of SARS‐CoV‐2 mRNA vaccine, 15 (65.3%) received three doses. Two (8.7%) had rejection; one with de novo DSA, another without. There was no difference in the number of doses of COVID‐19 vaccine received in those with rejection vs. no rejection ( p = 0.53). 13 (56.5%) developed SARS‐CoV‐2 infection, with no difference in the number of vaccines received between those infected with COVID‐19 vs. those who were not ( p = 0.69). No adjustments were made to the maintenance immunosuppression during SARS‐CoV‐2 infection, and there was no evidence of rejection or DSA formation after infection. Median follow‐up time was 29.9 months (IQR 25.0–33.4 months) after the first vaccine dose. Conclusion: In our small single‐center cohort, SARS‐CoV‐2 vaccination or infection is unlikely to increase the risk for rejection or de novo DSA in pediatric kidney transplant recipients. Larger prospective studies with a control group are needed to further understand the immune effects of the COVID‐19 vaccine and disease in this population.Keywords
This publication has 36 references indexed in Scilit:
- Development of donor specific antibodies after SARS-CoV-2 vaccination in kidney and heart transplant recipientsTransplant Immunology, 2022
- SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodiesTransplant Immunology, 2022
- COVID-19 in pediatric kidney transplantation: a follow-up report of the Improving Renal Outcomes CollaborativePediatric Nephrology, 2022
- Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression ModulationKidney International Reports, 2022
- Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipientsKidney International, 2021
- COVID-19 vaccine does not alter panel reactive antibody or flow cytometric cross match in kidney transplant candidatesTransplant Immunology, 2021
- Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort studyClinical Microbiology and Infection, 2021
- Acute rejection after anti–SARS-CoV-2 mRNA vaccination in a patient who underwent a kidney transplantKidney International, 2021
- Chronic Active Antibody-Mediated Rejection Following COVID-19 Infection in a Kidney Transplant Recipient: A Case ReportTransplantation Proceedings, 2021
- Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysisThe Journal of Heart and Lung Transplantation, 2018